We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Dispute Over Exclusivity Emerges As Latest Biosimilars Battle
Dispute Over Exclusivity Emerges As Latest Biosimilars Battle
January 28, 2011
As the FDA works behind the scenes to determine how it will regulate the approval pathway for biosimilars, a debate between brand- and generic-drug makers is brewing over how the exclusivity period included in the pathway should work.